June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
18 citations
,
January 2019 in “International journal of trichology” The treatment improved hair growth in three patients with alopecia.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
April 2025 in “International Journal of Dermatology” Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.
46 citations
,
December 2001 in “Journal of Endocrinology/Journal of endocrinology” FLRG and follistatin have different roles in wound healing.
April 2023 in “Journal of Investigative Dermatology” Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.
February 2023 in “Military Medical Science Letters” Platelet-rich plasma treatments reduce knee osteoarthritis inflammation, with pure PRP being more effective.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
2 citations
,
August 2020 in “Journal of Cosmetic Dermatology” Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Topical JAK inhibitors may help children with alopecia areata regrow hair.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
April 2024 in “Journal of cosmetic dermatology” Platelet-rich fibrin might be a promising treatment for hair loss, but more research is needed to confirm its effectiveness.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
January 2020 in “International Journal of Trichology” PRP injections are not effective for long-term treatment of temporal triangular alopecia.
13 citations
,
October 2013 in “Dermatologic Therapy” ATE is linked to FAA, and treatment depends on cause; minoxidil helps, finasteride may worsen.
15 citations
,
May 2003 in “American Journal of Kidney Diseases” A hemodialysis patient's hair loss was caused by the drug tinzaparin but stopped after switching to a different drug.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
February 2026 in “Frontiers in Pharmacology” Platelet-rich plasma can help heal difficult gastrointestinal fistulas after surgery.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
14 citations
,
February 2021 in “Journal of the European Academy of Dermatology and Venereology” A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
May 2024 in “Clinical and experimental optometry”
April 2022 in “The Egyptian Journal of Hospital Medicine” Platelet Rich Fibrin improves healing and reduces acne scars by slowly releasing growth factors.
March 2026 in “Frontiers in Pharmacology” Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
11 citations
,
January 2020 in “Journal of Drugs in Dermatology” Intralesional triamcinolone acetonide is effective and safe for treating early to mid-stage traction alopecia.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.